Symbols / LFCR Stock $5.65 +0.00% Lifecore Biomedical, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
LFCR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Paul Josephs
Exch · Country NMS · United States
Market Cap 211.93M
Enterprise Value 390.49M
Income -34.50M
Sales 129.46M
FCF (ttm) —
Book/sh -0.38
Cash/sh 0.55
Employees 382
Insider 10d —
IPO Feb 15, 1996
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.98
PEG 2.66
P/S 1.64
P/B -14.91
P/C —
EV/EBITDA 47.38
EV/Sales 3.02
Quick Ratio 2.18
Current Ratio 3.49
Debt/Eq 722.60
LT Debt/Eq —
EPS (ttm) -1.27
EPS next Y -0.81
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA —
ROE —
ROIC —
Gross Margin 31.37%
Oper. Margin -13.25%
Profit Margin -23.78%
Shs Outstand 37.51M
Shs Float 19.36M
Insider Own 2.83%
Instit Own 77.19%
Short Float 7.72%
Short Ratio 12.21
Short Interest 2.35M
52W High 8.98
vs 52W High -37.08%
52W Low 3.63
vs 52W Low 55.65%
Beta 1.07
Impl. Vol. 44.08%
Rel Volume 0.05
Avg Volume 345.71K
Volume 18.34K
Target (mean) $6.67
Tgt Median $6.00
Tgt Low $5.00
Tgt High $9.00
# Analysts 3
Recom None
Prev Close $5.65
Price $5.65
Change 0.00%
About

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.67
Mean price target
2. Current target
$5.65
Latest analyst target
3. DCF / Fair value
$6.67
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$5.65
Low
$5.00
High
$9.00
Mean
$6.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main Barrington Research Outperform → Outperform $6
2026-03-27 main Barrington Research Outperform → Outperform $6
2026-03-24 main Barrington Research Outperform → Outperform $6
2026-03-17 up Barrington Research Market Perform → Outperform $6
2025-09-04 init Keybanc — → Sector Weight —
2025-05-21 init William Blair — → Outperform —
2025-01-03 reit Stephens & Co. Equal-Weight → Equal-Weight $6
2024-11-22 main Craig-Hallum Buy → Buy $10
2024-09-05 init Craig-Hallum — → Buy $8
2024-08-28 down Barrington Research Outperform → Market Perform —
2023-09-01 main Barrington Research Outperform → Outperform $10
2023-09-01 main Stephens & Co. Equal-Weight → Equal-Weight $9
2023-06-02 main Barrington Research Outperform → Outperform $11
2023-05-24 main Barrington Research Outperform → Outperform $10
2023-03-21 main Barrington Research — → Outperform $8
2023-03-20 main Barrington Research — → Outperform $8
2023-03-20 down Stephens & Co. Overweight → Equal-Weight $2
2023-03-17 reit Stephens & Co. — → Overweight $11
News
RSS: Latest LFCR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-04 OBUS NELSON Director — 25,907 $0.00 $0
2026-06-04 KIPER CHRISTOPHER S Director and Beneficial Owner of more than 10% of a Class of Security — 25,907 $0.00 $0
2026-06-04 HOUDE KATRINA LOVAS Director — 25,907 $0.00 $0
2026-06-04 KORENBERG MATTHEW E Director — 25,907 $0.00 $0
2026-06-04 SCHECHTER JOSHUA E Director — 25,907 $0.00 $0
2026-06-04 ARYEH JASON M Director — 25,907 $0.00 $0
2026-06-04 ANTUNES HUMBERTO CALHEIROS Director — 25,907 $0.00 $0
2026-06-04 JOHNSON PAUL HAROLD Director — 25,907 $0.00 $0
2026-03-02 SALUS THOMAS D Officer — 30,000 $0.00 $0
2025-07-15 OBUS NELSON Director — 19,506 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Total Revenue
128.87
+0.47%
128.26
+24.20%
103.27
-7.19%
111.27
Operating Revenue
128.87
+0.47%
128.26
+24.20%
103.27
-7.19%
111.27
Cost Of Revenue
88.57
+2.50%
86.41
+14.78%
75.28
+4.27%
72.20
Reconciled Cost Of Revenue
88.57
+2.50%
86.41
+14.78%
75.28
+4.27%
72.20
Gross Profit
40.30
-3.71%
41.85
+49.54%
27.98
-28.36%
39.07
Operating Expense
52.30
+6.66%
49.04
+2.79%
47.70
+12.25%
42.50
Research And Development
8.26
-3.70%
8.57
-1.84%
8.74
+11.44%
7.84
Selling General And Administration
44.05
+8.86%
40.46
+3.83%
38.97
+12.44%
34.66
Total Expenses
140.87
+4.00%
135.45
+10.13%
122.99
+7.22%
114.70
Operating Income
-12.01
-67.03%
-7.19
+63.55%
-19.72
-474.59%
-3.43
Total Operating Income As Reported
-17.25
-94.99%
-8.84
+59.42%
-21.80
-84.85%
-11.79
EBITDA
-8.48
-123.81%
35.62
+207.37%
-33.17
-358.25%
12.84
Normalized EBITDA
-3.65
-63.78%
-2.23
+69.70%
-7.35
-134.68%
21.20
Reconciled Depreciation
8.03
+0.92%
7.95
-39.64%
13.18
-27.04%
18.06
EBIT
-16.51
-159.67%
27.66
+159.68%
-46.35
-788.38%
-5.22
Total Unusual Items
-4.83
-112.76%
37.84
+246.59%
-25.82
-208.85%
-8.36
Total Unusual Items Excluding Goodwill
-4.83
-112.76%
37.84
+246.59%
-25.82
-208.85%
-8.36
Special Income Charges
-5.24
-216.36%
-1.66
+93.59%
-25.82
-208.85%
-8.36
Other Special Charges
—
—
23.74
—
Impairment Of Capital Assets
—
—
—
28.73
Restructuring And Mergern Acquisition
-1.75
-205.50%
1.66
-60.42%
4.18
-49.95%
8.36
Net Income
-38.72
-422.29%
12.01
+112.07%
-99.56
+14.70%
-116.72
Pretax Income
-38.67
-506.50%
9.51
+114.88%
-63.93
-209.02%
-20.69
Net Non Operating Interest Income Expense
-21.84
-20.70%
-18.09
-2.90%
-17.58
-13.65%
-15.47
Interest Expense Non Operating
22.17
+22.15%
18.15
+3.23%
17.58
+13.65%
15.47
Net Interest Income
-21.84
-20.70%
-18.09
-2.90%
-17.58
-13.65%
-15.47
Interest Expense
22.17
+22.15%
18.15
+3.23%
17.58
+13.65%
15.47
Interest Income Non Operating
0.33
+474.14%
0.06
-14.71%
0.07
-16.05%
0.08
Interest Income
0.33
+474.14%
0.06
-14.71%
0.07
-16.05%
0.08
Other Income Expense
-4.83
-113.89%
34.79
+230.66%
-26.63
-1391.71%
-1.78
Other Non Operating Income Expenses
-0.00
+99.90%
-3.05
-276.79%
-0.81
-112.32%
6.57
Gain On Sale Of Security
0.41
-98.96%
39.50
—
—
Gain On Sale Of Business
—
0.00
-100.00%
2.11
0.00
Tax Provision
0.04
-76.50%
0.18
-40.58%
0.31
+105.91%
-5.21
Tax Rate For Calcs
0.00
+991.76%
0.00
-90.84%
0.00
-16.63%
0.00
Tax Effect Of Unusual Items
-1.01
-239.34%
0.73
+113.43%
-5.42
-157.48%
-2.11
Net Income Including Noncontrolling Interests
-38.72
-422.29%
12.01
+112.07%
-99.56
+14.70%
-116.72
Net Income From Continuing Operation Net Minority Interest
-38.72
-514.93%
9.33
+114.53%
-64.24
-315.07%
-15.48
Net Income From Continuing And Discontinued Operation
-38.72
-422.29%
12.01
+112.07%
-99.56
+14.70%
-116.72
Net Income Continuous Operations
-38.72
-514.93%
9.33
+114.53%
-64.24
-315.07%
-15.48
Net Income Discontinuous Operations
0.00
-100.00%
2.68
+107.59%
-35.33
+65.11%
-101.24
Normalized Income
-34.90
-25.61%
-27.79
+36.62%
-43.84
-375.36%
-9.22
Net Income Common Stockholders
-44.36
-469.26%
12.01
+112.07%
-99.56
+14.70%
-116.72
Otherunder Preferred Stock Dividend
2.32
0.00
—
—
Diluted EPS
-1.27
-496.88%
0.32
+109.38%
-3.41
-3.33%
-3.30
Basic EPS
-1.27
-417.50%
0.40
+111.73%
-3.41
-3.50%
-3.29
Basic Average Shares
34.82
+14.26%
30.47
+1.69%
29.97
+1.54%
29.51
Diluted Average Shares
34.82
-5.02%
36.66
+22.32%
29.97
+1.54%
29.51
Diluted NI Availto Com Stockholders
-44.36
-469.26%
12.01
+112.07%
-99.56
+14.70%
-116.72
Gain On Sale Of PPE
-6.99
0.00
—
—
Preferred Stock Dividends
3.32
—
—
—
Line Item Trend 2025-12-31 2025-05-31 2024-05-31 2023-05-31
Total Assets
232.18
-2.99%
239.34
-5.76%
253.96
+0.16%
253.54
Current Assets
82.29
-3.95%
85.68
+5.73%
81.03
-13.68%
93.88
Cash Cash Equivalents And Short Term Investments
17.47
+111.36%
8.27
-2.33%
8.46
-55.68%
19.09
Cash And Cash Equivalents
17.47
+111.36%
8.27
-2.33%
8.46
-55.68%
19.09
Receivables
33.82
-22.56%
43.67
+40.17%
31.15
+7.34%
29.02
Accounts Receivable
26.16
-8.81%
28.69
+5.92%
27.08
-6.68%
29.02
Gross Accounts Receivable
27.21
-9.43%
30.04
+8.07%
27.80
-5.81%
29.51
Allowance For Doubtful Accounts Receivable
-1.04
+22.72%
-1.35
-90.01%
-0.71
-46.60%
-0.48
Other Receivables
7.66
+9.69%
6.98
+71.52%
4.07
—
Inventory
29.09
-9.93%
32.29
-19.23%
39.98
-2.11%
40.84
Raw Materials
10.09
-0.76%
10.17
-22.61%
13.14
-25.91%
17.73
Work In Process
7.15
-18.24%
8.74
-26.62%
11.91
+15.13%
10.35
Finished Goods
11.85
-11.47%
13.38
-10.35%
14.92
+13.57%
13.14
Prepaid Assets
—
—
—
—
Assets Held For Sale Current
—
—
—
0.00
Other Current Assets
1.92
+32.12%
1.45
+1.04%
1.44
-70.75%
4.92
Total Non Current Assets
149.88
-2.46%
153.66
-11.14%
172.93
+8.30%
159.67
Net PPE
127.30
-1.32%
129.01
-13.51%
149.16
+7.57%
138.67
Gross PPE
186.46
+0.02%
186.42
-6.56%
199.50
+1.95%
195.68
Accumulated Depreciation
-59.16
-3.04%
-57.41
-14.06%
-50.33
+11.70%
-57.01
Properties
0.00
0.00
0.00
0.00
Land And Improvements
3.49
-6.63%
3.74
+0.00%
3.74
+0.00%
3.74
Buildings And Improvements
82.02
+28.70%
63.73
+1.36%
62.87
+3.60%
60.69
Machinery Furniture Equipment
91.41
+28.41%
71.19
+0.36%
70.93
-8.31%
77.36
Construction In Progress
9.54
-80.03%
47.76
-22.91%
61.95
+35.90%
45.59
Other Properties
—
—
2.44
-42.97%
4.28
Leases
—
—
0.00
-100.00%
4.02
Goodwill And Other Intangible Assets
13.88
+0.00%
13.88
+0.00%
13.88
-23.23%
18.08
Goodwill
13.88
+0.00%
13.88
+0.00%
13.88
+0.00%
13.88
Other Intangible Assets
—
4.20
+0.00%
4.20
+0.00%
4.20
Other Non Current Assets
8.70
-19.28%
10.78
+9.08%
9.88
+238.74%
2.92
Total Liabilities Net Minority Interest
246.38
+3.52%
238.01
-1.91%
242.65
-5.87%
257.77
Current Liabilities
23.57
-21.89%
30.18
-22.37%
38.87
-1.06%
39.29
Payables And Accrued Expenses
7.54
-49.56%
14.95
-38.06%
24.14
-17.45%
29.24
Payables
5.84
-54.09%
12.72
-35.78%
19.80
-10.37%
22.10
Accounts Payable
5.84
-28.97%
8.22
-49.68%
16.33
-26.08%
22.10
Other Payable
—
4.50
+29.62%
3.47
—
Current Accrued Expenses
1.70
-23.75%
2.23
-48.46%
4.33
-39.36%
7.14
Pensionand Other Post Retirement Benefit Plans Current
4.55
-25.98%
6.14
-0.34%
6.17
+48.73%
4.14
Current Debt And Capital Lease Obligation
1.33
-65.32%
3.82
-22.05%
4.91
+165.19%
1.85
Current Debt
0.77
-77.51%
3.44
+264.48%
0.94
+62.59%
0.58
Other Current Borrowings
0.77
-77.51%
3.44
+264.48%
0.94
+62.59%
0.58
Current Capital Lease Obligation
0.55
+42.89%
0.39
-90.23%
3.96
+212.05%
1.27
Current Deferred Liabilities
8.66
+153.59%
3.42
+61.62%
2.11
-47.89%
4.05
Current Deferred Revenue
8.66
+153.59%
3.42
+61.62%
2.11
-47.89%
4.05
Other Current Liabilities
1.50
-18.76%
1.84
+18.81%
1.55
—
Total Non Current Liabilities Net Minority Interest
222.81
+7.21%
207.83
+1.99%
203.77
-6.73%
218.49
Liabilities Heldfor Sale Non Current
—
—
—
0.00
Long Term Debt And Capital Lease Obligation
141.28
+11.25%
127.00
+2.65%
123.72
+11.69%
110.77
Long Term Debt
135.59
+6.76%
127.00
+2.65%
123.72
+22.42%
101.06
Long Term Capital Lease Obligation
5.69
—
4.94
-49.08%
9.71
Non Current Deferred Liabilities
—
—
5.25
+58.01%
3.32
Non Current Deferred Revenue
—
—
4.70
+59.97%
2.94
Non Current Deferred Taxes Liabilities
—
—
0.54
+42.89%
0.38
Other Non Current Liabilities
6.70
-31.24%
9.74
-19.24%
12.06
+6831.61%
0.17
Preferred Securities Outside Stock Equity
48.26
+4.70%
46.10
+8.24%
42.59
+8.31%
39.32
Stockholders Equity
-14.20
-1163.02%
1.34
-88.19%
11.31
+367.49%
-4.23
Common Stock Equity
-14.20
-1163.02%
1.34
-88.19%
11.31
+367.49%
-4.23
Capital Stock
0.04
+0.00%
0.04
+19.35%
0.03
+3.33%
0.03
Common Stock
0.04
+0.00%
0.04
+19.35%
0.03
+3.33%
0.03
Share Issued
37.48
+1.22%
37.03
+21.15%
30.56
+3.56%
29.51
Ordinary Shares Number
37.48
+1.22%
37.03
+21.15%
30.56
+3.56%
29.51
Additional Paid In Capital
208.96
+1.17%
206.54
+16.16%
177.81
+2.03%
174.28
Retained Earnings
-223.20
-8.75%
-205.24
-23.25%
-166.52
+6.73%
-178.54
Gains Losses Not Affecting Retained Earnings
—
—
—
0.00
Other Equity Adjustments
—
—
—
—
Total Equity Gross Minority Interest
-14.20
-1163.02%
1.34
-88.19%
11.31
+367.49%
-4.23
Total Capitalization
121.39
-5.41%
128.34
-4.97%
135.04
+39.45%
96.83
Working Capital
58.72
+5.80%
55.50
+31.64%
42.16
-22.76%
54.59
Invested Capital
122.16
-7.30%
131.77
-3.10%
135.98
+39.59%
97.42
Total Debt
142.61
+9.01%
130.82
+1.70%
128.63
+14.21%
112.62
Net Debt
118.89
-2.68%
122.17
+5.13%
116.21
+40.76%
82.55
Capital Lease Obligations
6.25
+1514.21%
0.39
-90.23%
3.96
-63.90%
10.98
Net Tangible Assets
-28.08
-123.86%
-12.54
-388.89%
-2.57
+88.50%
-22.31
Tangible Book Value
-28.08
-123.86%
-12.54
-388.89%
-2.57
+88.50%
-22.31
Derivative Product Liabilities
26.56
+6.29%
24.99
-1.61%
25.40
-60.86%
64.90
Inventories Adjustments Allowances
—
—
-1.42
-268.49%
-0.38
Line Of Credit
—
—
—
0.00
Notes Receivable
0.00
-100.00%
8.00
0.00
—
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Operating Cash Flow
-0.21
-180.16%
0.26
+101.47%
-17.44
+22.80%
-22.59
Cash Flow From Continuing Operating Activities
-0.21
-180.16%
0.26
+101.47%
-17.44
+22.80%
-22.59
Net Income From Continuing Operations
-38.72
-422.29%
12.01
+112.07%
-99.56
+14.70%
-116.72
Depreciation Amortization Depletion
8.03
+0.92%
7.95
-39.64%
13.18
-27.04%
18.06
Depreciation
8.03
+0.92%
7.95
-40.13%
13.29
-25.72%
17.88
Depreciation And Amortization
8.03
+0.92%
7.95
-39.64%
13.18
-27.04%
18.06
Other Non Cash Items
17.65
+2.22%
17.27
+1515.53%
1.07
+350.94%
-0.43
Stock Based Compensation
10.16
+63.81%
6.20
+71.68%
3.61
+38.50%
2.61
Provisionand Write Offof Assets
—
0.26
+61.35%
0.16
+1264.29%
-0.01
Asset Impairment Charge
—
0.00
-100.00%
1.30
-98.34%
78.15
Deferred Tax
—
0.16
-54.34%
0.36
+105.23%
-6.83
Deferred Income Tax
—
0.16
-54.34%
0.36
+105.23%
-6.83
Operating Gains Losses
7.37
+118.66%
-39.48
-192.57%
42.65
+651.86%
5.67
Gain Loss On Investment Securities
-0.41
+98.96%
-39.50
—
—
Gain Loss On Sale Of PPE
7.78
+43100.00%
0.02
-52.63%
0.04
-99.29%
5.34
Change In Working Capital
-4.70
-26.93%
-3.70
-118.69%
19.79
+738.21%
-3.10
Change In Receivables
-5.17
-116.22%
-2.39
-122.10%
10.82
+276.34%
-6.14
Changes In Account Receivables
-2.26
+30.68%
-3.26
-130.15%
10.82
+276.34%
-6.14
Change In Inventory
7.69
+791.88%
0.86
+105.82%
-14.81
-579.40%
-2.18
Change In Prepaid Assets
—
—
2.16
+458.14%
-0.60
Change In Payables And Accrued Expense
-7.59
-51.09%
-5.02
-132.31%
15.55
+162.42%
5.92
Change In Accrued Expense
-5.92
-458.08%
1.65
+435.98%
-0.49
+85.61%
-3.42
Change In Payable
-1.67
+74.99%
-6.68
-141.63%
16.04
+71.66%
9.34
Change In Account Payable
-1.67
+74.99%
-6.68
-141.63%
16.04
+71.66%
9.34
Change In Other Working Capital
—
-0.18
-102.95%
6.08
+33855.56%
-0.02
Change In Other Current Assets
0.38
-86.76%
2.85
+32.37%
2.16
+412.92%
-0.69
Investing Cash Flow
-6.42
+65.13%
-18.39
-282.35%
-4.81
-106.02%
79.96
Cash Flow From Continuing Investing Activities
-6.42
+65.13%
-18.39
-282.35%
-4.81
-106.02%
79.96
Net PPE Purchase And Sale
-6.42
+65.13%
-18.39
+14.37%
-21.48
+25.41%
-28.80
Purchase Of PPE
-13.41
+27.07%
-18.39
+14.37%
-21.48
+28.25%
-29.94
Sale Of PPE
7.00
0.00
0.00
-100.00%
1.14
Capital Expenditure
-13.41
+27.07%
-18.39
+14.37%
-21.48
+28.25%
-29.94
Net Investment Purchase And Sale
—
0.00
0.00
-100.00%
45.10
Sale Of Investment
—
0.00
0.00
-100.00%
45.10
Net Business Purchase And Sale
—
0.00
-100.00%
16.67
-77.32%
73.50
Purchase Of Business
—
—
0.00
+100.00%
-9.84
Gain Loss On Sale Of Business
—
0.00
-100.00%
18.87
+5517.26%
0.34
Net Other Investing Changes
—
—
—
-9.84
Financing Cash Flow
6.42
-14.45%
7.51
-81.09%
39.70
+169.62%
-57.02
Cash Flow From Continuing Financing Activities
6.42
-14.45%
7.51
-81.09%
39.70
+169.62%
-57.02
Net Issuance Payments Of Debt
-14.79
-613.22%
2.88
-7.63%
3.12
+105.63%
-55.41
Issuance Of Debt
130.97
-12.45%
149.59
-17.56%
181.45
+141.58%
75.11
Repayment Of Debt
-145.76
+0.64%
-146.70
+17.73%
-178.33
-36.63%
-130.52
Long Term Debt Issuance
130.97
-12.45%
149.59
-17.56%
181.45
+141.58%
75.11
Long Term Debt Payments
-145.76
+0.64%
-146.70
+17.73%
-178.33
-36.63%
-130.52
Net Long Term Debt Issuance
-14.79
-613.22%
2.88
-7.63%
3.12
+105.63%
-55.41
Short Term Debt Issuance
—
—
31.45
-42.93%
55.11
Short Term Debt Payments
—
—
-54.64
-23.87%
-44.11
Net Short Term Debt Issuance
—
—
-54.64
-23.87%
-44.11
Net Common Stock Issuance
23.85
0.00
-100.00%
4.82
0.00
Proceeds From Stock Option Exercised
-1.27
-735.53%
-0.15
0.00
0.00
Net Other Financing Charges
-1.36
-128.56%
4.78
+175.57%
-6.32
-292.80%
-1.61
Changes In Cash
-0.20
+98.15%
-10.63
-160.92%
17.45
+4913.79%
0.35
Beginning Cash Position
8.46
-55.68%
19.09
+1061.96%
1.64
+26.87%
1.29
End Cash Position
8.27
-2.33%
8.46
-55.68%
19.09
+1061.96%
1.64
Free Cash Flow
-13.62
+24.90%
-18.14
+53.40%
-38.92
+25.91%
-52.53
Interest Paid Supplemental Data
1.91
-30.15%
2.73
-91.20%
31.02
+83.70%
16.89
Income Tax Paid Supplemental Data
0.05
-36.11%
0.07
+213.04%
0.02
-94.78%
0.44
Common Stock Issuance
23.85
0.00
-100.00%
4.82
0.00
Issuance Of Capital Stock
23.85
0.00
-100.00%
42.90
0.00
Net Preferred Stock Issuance
—
0.00
-100.00%
38.08
0.00
Preferred Stock Issuance
—
0.00
-100.00%
38.08
0.00
Sale Of Business
—
0.00
-100.00%
16.67
-77.32%
73.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category